Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, HNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.
Cocklin
Simon
S
Drexel University College of Medicine, 11313 New College Building, 245 N. 15th St., Philadelphia, PA 19102, USA. sc349@drexel.edu
Gopi
Hosahudya
H
Querido
Bianca
B
Nimmagadda
Manideepthi
M
Kuriakose
Syna
S
Cicala
Claudia
C
Ajith
Sandya
S
Baxter
Sabine
S
Arthos
James
J
Martín-García
Julio
J
Chaiken
Irwin M
IM
D019380:Anti-HIV Agents / Q000737:chemistry* / Q000494:pharmacology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects*; D015394:Molecular Structure; D010446:Peptide Fragments / Q000378:metabolism*; D013329:Structure-Activity Relationship; D020349:Surface Plasmon Resonance; D053586:Virus Internalization / Q000187:drug effects*
D019380:Anti-HIV Agents; D015699:HIV Envelope Protein gp120; D010446:Peptide Fragments